ClinicalTrials.gg
WithdrawnNCT06881823NeoPSMAUpdated Dec 29, 2025

Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC

A Phase 1/2 interventional study of AAA602 and AAA802 in Prostate Cancer, sponsored by Novartis Pharmaceuticals. Withdrawn. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
The radioligands to be evaluated showed acceptable safety but limited benefit in metastatic prostate cancer

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing Lutetium-177 in Prostatic Neoplasms — 8 open to participants now, 10 under way, none of them phase 3. Lutetium-177 · Prostatic Neoplasms.

Enrollment
14th of 14
0 · median 31
Started
2026
with 3 others
Phase 1/2
4 of 14
3 open now
Registered
10th of 14
by date
Lead sponsor
4 of 14
Novartis Pharmaceuticals

Among the 14 studies testing Lutetium-177 in Prostatic Neoplasms, this one is the 14th largest by enrollment, is one of 4 that started in 2026, is one of 4 in phase 1/2, and was the 10th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 14 studies testing Lutetium-177 in Prostatic Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About Lutetium-177

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 100 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing Lutetium-177 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this trial is to learn more about the effects of AAA602 and AAA802 in men with prostate-specific membrane antigen (PSMA) positive high-risk localized prostate cancer (HRLPC) before surgery to remove the prostate and lymph nodes present in the pelvis area. Lymph nodes are small structures near the prostate that help fight infections. These lymph nodes are removed during surgery because they are a site the disease can spread to.

Read the detailed description

This Phase I/II study is intended to determine the safety, tolerability, anti-tumor activity, pharmacokinetics, and dosimetry of neoadjuvant treatment with the radioligand therapies (RLT) [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) before surgery, i.e., radical prostatectomy (RP) and pelvic lymph node dissection (PLND), in participants with Prostate-Specific Membrane Antigen (PSMA)-positive high-risk localized prostate cancer (HRLPC).

Study CAAA802B12101 is a Phase I/II open-label, multi-center study investigating AAA602 and AAA802 as neoadjuvant RLTs before surgery in participants with PSMA-positive HRLPC. In Phase I, participants will be assigned to AAA602 or AAA802 dose escalation cohorts to determine the respective maximum tolerated dose (MTD) and/or the recommended dose for Phase II (RP2D). In Phase II, participants will be randomized to one or two investigational arms, i.e., the RP2D of AAA602 or AAA802, or to the control arm. Therefore, Phase II will have two or three treatment arms. In the control arm, participants will be treated with the standard of care (SoC), i.e., they will not receive any neoadjuvant treatment. Supportive care will be allowed.

Following the last dose of completed RLT, participants will complete a post-treatment imaging/Safety follow-up visit. Upon discontinuation of RLT, participants will complete an end of treatment (EOT) visit prior to the post-treatment imaging/Safety follow-up visit.

If participants undergo surgery, the post-treatment imaging/Safety follow-up visit will be performed before undergoing surgery.

After surgery, participants will complete a post-surgery visit and enter the LTFU. No adjuvant treatment is allowed between surgery and biochemical recurrence (BCR).

The investigational treatments in both Phases I and II are neoadjuvant treatment with AAA602 or AAA802 before surgery (RP and PLND). Surgery is to be performed as per the SoC and is not part of the investigational treatment in this study.

The control treatment in Phase II is SoC, i.e., no neoadjuvant treatment.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • High Risk Localized Prostate Cancer
  • prostate-specific membrane antigen
  • PSMA
  • neoadjuvant treatment
  • adults
  • radioligand therapies
  • RLT
  • AAA602
  • AAA802
  • Prostate cancer
  • Phase 1
  • Phase 2
  • high-risk localized prostate cancer
  • HRLPC
  • Actinium
  • Lutetium
  • gozetotide
  • Radical Prostatectomy
  • RP
  • Pelvic Lymph Node Dissection
  • PLND
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 18 years of age.
  • Participants must have PSMA-positive disease as assessed by PSMA PET/CT scan using a PSMA imaging agent as protocol instructed, with eligibility being determined by the sponsor's central reading rules.
  • confirmed high-risk adenocarcinoma of an intact prostate, and (a) 1 of the following at diagnosis: Gleason score ≥ 8 and/or PSA ≥ 20 nanogram per milliliters (ng/mL), and/or ≥ cT3a or (b) Gleason score 4+3 and PSA ≥ 20 nanogram per milliliters (ng/mL).
  • Adequate organ function:
  • Bone marrow reserve:
  • White blood cell (WBC) count ≥ 3.0 x 109/L and (ANC) ≥ 1.5 x 109/L.
  • ≥ 75 x 109/L.
  • ≥ 8 g/dL
  • Hepatic function:
  • Total ≤ 1.5 x the institutional (ULN). For participants with known Gilbert's Syndrome ≤ 3 x ULN is permitted.
  • (ALT) and aspartate aminotransferase (AST) ≤ 3.0 x ULN
  • Albumin > 3.0 g/dL
  • Renal function:
  • ≥ 60 mL/min. Note that participants with findings indicating blockage of urinary outflow are not eligible. No evidence of congenital renal abnormalities with known effect on renal function or voiding abnormalities that may interfere, in the opinion of the principal investigator, with the safe administration of the study treatment.
  • An (ECOG) Performance Status (PS) of 0 or 1.
  • Indicated to receive radical prostatectomy (RP) and pelvic lymph node dissection (PLND).
  • Sexually active participants with female partners of are eligible to participate if they agree to follow one of the following methods of consistently, starting from screening, during the study and for at least 6 months after the last dose of study treatment:
  • Are abstinent from penile-vaginal intercourse as their usual and preferred lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent.
  • Are sterilized (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate);
  • Agree to use a male condom and have their partner use a highly effective method of contraception (failure rate \< 1% per year) as described in Section 8.4.6 when having penile-vaginal intercourse with a woman of childbearing potential who is not currently pregnant, and who agrees to the use of a condom by her partner.
  • In addition, participants must refrain from donating sperm starting from Screening, during the study and for at least 6 months after the last dose of the study medication.
  • Sexually active participants with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse; or use a male condom during each episode of penile penetration during the study.

Exclusion criteria

Exclusion Criteria:

  • Subjects taking prohibited therapies as described in the protocol
  • Any approved or systemic anti-cancer therapy (e.g. chemotherapy, investigational therapy, immunotherapy or biological therapy including monoclonal antibodies) administered for the treatment of HRLPC within 28 days (or 5 times the half-life of that therapy whichever is longer) of the anticipated day C1D1.
  • Previous treatment with any approved or investigational radioligand therapy, approved or investigational radioisotopes.
  • Prior or concurrent radiation therapy of the prostate, other prostate antineoplastic ablative procedures, or hormonal ablation for prostate cancer.
  • Diagnosed with other active that are expected to alter or may interfere with disease assessment. Participants with a prior history of malignancy that has been adequately treated and who have been disease free and treatment free for more than 3 years prior to randomization are eligible, as are participants with adequately treated non-melanoma skin cancer and superficial bladder cancer.

Other protocol-defined Inclusion/exclusion may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    AAA602

    AAA602 will be administered as a single intravenous dose. Dose escalation and de-escalation steps will be performed in accordance with the BOIN design.

    Drug: AAA602 · Drug: Gallium (68Ga) gozetotide · Drug: Piflufolastat (18F) · Drug: Flotufolastat F 18 · Drug: 18F-PSMA-1007

  • Active comparator
    AAA802

    AAA802 will be administered as a single intravenous dose Dose escalation/de-escalation steps will be performed in accordance with the BOIN design.

    Drug: AAA802 · Drug: Gallium (68Ga) gozetotide · Drug: Piflufolastat (18F) · Drug: Flotufolastat F 18 · Drug: 18F-PSMA-1007

  • No intervention
    Control Arm

    No neoadjuvant treatment

Interventions

  • DrugAAA602

    \[177\]Lu-PSMA-R2 Radiopharmaceutical solution for injection/infusion.

    Also known as: Lutetium-177

  • DrugAAA802

    \[225\]Actinium-PSMA-R2 radiopharmaceutical solution for injection/infusion

    Also known as: Actinium-225

  • Radioligand Imaging compound. Provided as a kit for radiopharmaceutical preparation of gallium (68Ga) gozetotide. Solution for injection.

    Also known as: Locametz, Illuccix

  • DrugPiflufolastat (18F)

    Radioligand Imaging compound. Provided as a ready-to-use radiopharmaceutical.

    Also known as: Pylarify, Pylclari

  • Radioligand Imaging compound. Provided as a ready to use radiopharamceutical.

    Also known as: Posluma

  • Drug18F-PSMA-1007

    Radioligand Imaging compound. Provided as a ready to use radiopharmaceutical.

    Also known as: Fluorine-18 PSMA 1007

06

What researchers measure

Primary outcomes

  1. Number of participants with dose-limiting toxicities (DLTs) (Phase l)

    Incidence and severity of dose-limiting toxicities.

    Time frame: At the end of cycle 1 (each cycle is maximum 6 weeks)

  2. Biochemical recurrence free survival (BFS) (Phase ll)

    BFS is defined as the time from the date of surgery until the date of confirmed biochemical recurrence (PSA \> 0.2 ng/mL on two readings separated by at least 4 weeks measured at least 8 weeks after surgery).

    Time frame: From the date of surgery until the date of confirmed biochemical recurrence or death due to any cause, whichever occurs first assessed to approximately 60 months

Secondary outcomes

  1. Biochemical response as measured as Prostate Specific Antigen (PSA)50 (Phase ll)

    PSA50 is defined as the percentage of participants who achieved a ≥ 50% decrease (that is confirmed by a second PSA measurement ≥ 4 weeks later) from baseline at the end of neoadjuvant treatment.

    Time frame: From screening until the end of neoadjuvant treatment assessed to approximately 6 months

  2. Overall Response Rate (ORR) at 12 months after surgery (Phase ll)

    ORR is the percentage of participants with a response without addition of any new antineoplastic therapy. Antineoplastic therapy is defined as PSA \< 0.2 ng/ml as per central lab at month 12 (that is confirmed by a second PSA measurement ≥ 4 weeks later).

    Time frame: at 12 months after surgery

  3. Change from baseline in domain scores of the EPIC-26 (Phase ll)

    EPIC-26 (expanded prostate cancer index composite) is a health related quality of life assessment. It contains five symptom domains (urinary incontinence, urinary irritative/obstructive, sexual, bowel, hormonal), scored from 0 (worst) to 100 (best), that can be tracked over time to understand symptom burden and functional outcomes.

    Time frame: From screening to end of long term follow up assessed up to approximately 66 months

  4. Change from baseline on FACT-GP5 item (Phase ll)

    FACT-GP5 (Functional assessment of Cancer Therapy item-GP5) is a health related assessment measuring the overall impact of treatment toxicity. The assessment consists of 1 question - 'I am bothered by side effects of treatment'. The scoring range goes from 0 (not at all) to 4 (very much).

    Time frame: From screening to end of long term follow up assessed up to approximately 66 months

  5. Overall Response Rate (ORR) (Phase l & ll)

    ORR is the percentage of participants with a complete biochemical response without addition of any new antineoplastic therapy other than the study medication (AAA602/AAA802 and/or Radical Prostatectomy (RP) and Pelvic Lymph Node Dissection (PLND)). Antineoplastic therapy is defined as PSA \< 0.2 ng/ml as per central lab (that is confirmed by a second PSA measurement ≥ 4 weeks later).

    Time frame: Month 12, Month 15, Month 18

  6. Percentage of participants with a functional response on PSMA PET/CT

    Functional response is defined as either complete PSMA response if all PSMA-avid lesions had resolved, a partial response if there was \>30% decrease in SUVmax, progressive disease if there was \>30% increase in SUVmax, or the presence of new PSMA-avid lesions and stable disease if the response did not meet the criteria for complete, partial, or progressive PSMA-avid disease. The response will be assessed at the end of neoadjuvant treatment with radioligand therapy compared to baseline (Eapen et al 2024).

    Time frame: From screening until the end of neoadjuvant treatment assessed to approximately 6 months

  7. Percentage of participants achieving pathological complete response (absence of disease) or minimal residual disease (Phase l & ll)

    Percentage of participants achieving pathological complete response (absence of disease) or minimal residual disease (Ph I \& II) as assessed by local review and independent central review.

    Time frame: From screening until post-surgery follow up assessed at approximately 7.5 months

  8. Concordance in the evaluation of pathological response between local review and independent central review (Phase l & ll)

    Correspondence between local and independent central assessment of participants achieving pathological complete response (absence of disease) or minimal residual disease.

    Time frame: From screening until post-surgery follow up assessed at approximately 7.5 months

  9. Radiation absorbed doses in organs and tumors of AAA602 (Phase l & ll)

    To evaluate tumor and organs dosimetry of AAA602.

    Time frame: From cycle 1 day 1 until until approximately cycle 2 day 3 (cycle is maximum 6 weeks)

  10. Time concentration profiles and Pharmacokinetics parameters of AAA802 and AAA602

    Time-concentration profiles and PK parameters of AAA602 and AAA802 (e.g. AUC, Cmax).

    Time frame: From cycle 1 day 1 until until approximately cycle 1 day 3 (cycle is maximum 6 weeks)

  11. Percentage of participants with surgical complications graded according to the Clavien-Dindo classification (Phase l & ll)To evaluate surgical safety (phase l & ll)

    Number and severity of complications based on the Clavien-Dindo classification (assessment performed post surgery). The Clavien Dindo Classification is used to rank the severity of a surgical complication. It is based on the type of therapy needed to correct the complication. The scale consists of several grades (Grade I, II, IIIa, IIIb, IVa, IVb and V). Grade I complications being the mildest and V being most significant.

    Time frame: From screening until post-surgery follow up assessed at approximately 7.5 months

  12. Percentage of participants achieving a complete response to therapy (Phase l & ll)

    Percentage of participants achieving undetectable PSA and absence of disease on PSMA PET/CT during neoadjuvant treatment. Complete response to safety is defined as: PSA \< 0.1 ng/ml that is confirmed by a second PSA measurement ≥ 4 weeks later; the absence of any PSMA uptake on PSMA PET/CT.

    Time frame: From screening until end cycle 2 assessed up to 20 weeks (cycle is maximum 6 weeks)

  13. Percentage of participants achieving PSA < 0.2 (Phase l & ll)

    Percentage of participants achieving undetectable PSA (\<0.2) after treatment with AAA802 and AAA602 post biochemical recurrence. PSA \< 0.2 is confirmed by a second PSA measurement ≥ 4 weeks later in response to treatment with cycles of AAA602 and/or AAA802 administered following biochemical recurrence after surgery;

    Time frame: From cycle 1 day 1 of post progression treatment to approximately 60 months after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

Data sharing details ↗ · www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Mar 2030, 45 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Mar 18, 2025
StartEst.
Jun 29, 2026
Primary completionEst.
Mar 31, 2030
CompletionEst.
Jun 1, 2033
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06881823
Responsible party
Sponsor
First posted
Mar 18, 2025
Start date
Jun 29, 2026 (estimated)
Primary completion
Mar 31, 2030 (estimated)
Completion
Jun 1, 2033 (estimated)
Last update
Dec 29, 2025

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lutetium-177 · Gallium 68 PSMA-11 · Flotufolastat F 18

Start the discussion